Truist downgraded Point Biopharma to Hold from Buy with a price target of $12.50, down from $13, after Eli Lilly (LLY) announced a definitive agreement to acquire Point for $12.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- H.C. Wainwright sees Actinium Pharmaceuticals as prime candidate for acquisition
- Eli Lilly deal for Point puts radiopharma names in spotlight
- JMP Securities remains bullish on Lantheus after Lilly’s acquisition of Point Biopharma
- Point Biopharma deal reads positively to radiopharma names, says B. Riley
- Lantheus jumps after Eli Lilly agrees to buy Point Biopharma